The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Open accessPublished version of a preprint
Abstract
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resistance to KRASG12C inhibitors remain undetermined. To begin to define the mechanistic spectrum of acquired resistance, we describe a patient with KRASG12C NSCLC who developed polyclonal acquired resistance to MRTX849 with the emergence of 10 heterogeneous resistance alterations in serial cell-free DNA spanning four genes (KRAS, NRAS, BRAF, MAP2K1), all of which converge to reactivate RAS–MAPK signaling. Notably, a novel KRASY96D mutation affecting the switch-II pocket, to which MRTX849 and other inactive-state inhibitors bind, was identified that interferes with key protein–drug interactions and confers resistance to these inhibitors in engineered and patient-derived KRASG12C cancer models. Interestingly, a novel, functionally distinct tricomplex KRASG12C active-state inhibitor RM-018 retained the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. Significance: In one of the first reports of clinical acquired resistance to KRASG12C inhibitors, our data suggest polyclonal RAS–MAPK reactivation as a central resistance mechanism. We also identify a novel KRAS switch-II pocket mutation that impairs binding and drives resistance to inactive-state inhibitors but is surmountable by a functionally distinct KRASG12C inhibitor. See related commentary by Pinnelli and Trusolino, p. 1874. This article is highlighted in the In This Issue feature, p. 1861
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired mutations of NRAS, BRAF, RTK, and MYC were also found in patients treated with sotorasib or adagrasib monotherapy [49, 51, 53, 54].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Point mutations in the KRAS gene included G12D/F/R/V/W, which prevent covalent interactions with mutant cysteine, as well as V8L, G13D, V14I, Q61H, H95D/Q/R, Y96C, and Y96D [62,97,102,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple mechanisms of acquired resistance have been identified, which largely converge on re-activation of the RAS pathway or alternatively activate parallel signaling pathways such as the PI3K/mTOR pathway10–14.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have recently described mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRASG12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vertical reactivation of the RAS pathway elements has been observed in most samples collected from patients who developed resistance to KRASG12C inhibitors.4,8,20,21”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In recent work, a case was described of an acquired Y96D switch II pocket mutation identified at a low variant allele frequency in ctDNA at the time of acquired resistance to adagrasib.23”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Many of the novel mutations were observed at low subclonal frequencies, contributing to tumor heterogeneity [97,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“While previous studies have characterized acquired resistance to KRASG12C inhibition and identified causal mutations and non-genetic mechanisms including RTK activation and epithelial-to-mesenchymal transition11–14,35, the mechanisms underlying differential sensitivity to KRASG12C inhibition are less well understood.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The genetic alterations identified in these studies are highly heterogeneous and may mediate therapeutic resistance via diverse mechanisms, such as changing inhibitor binding affinity, reactivating KRAS activity, and bypassing KRAS-mediated signaling [54, 56].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Prior studies indicated that tumors with acquired resistance to KRASG12C agents can have multiple resistance mechanisms, including alterations within the RAS/MAPK pathway and bypass activating alterations”
From Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer (2023) · cites this paper as [29]
In the citing paper
“RM-018 (13), developed by Revolution Medicines, covalently binds to the activated state of KRASG12C mutants, forms a ternary complex with cyclophilin A and KRASG12C, thereby inhibiting their activity.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [81]
In the citing paper
“Meanwhile, RM-018 retained the ability to bind and inhibit KRASG12C/Y96D, thus overcoming drug resistance.81”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [81]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [18]
In the citing paper
“Nonetheless, there remains an ongoing need for improved clinical outcomes (21), especially since emerging data indicate multiple mechanisms of acquired resistance in patients treated with sotorasib or adagrasib (22–24), many of which involve RAS pathway reactivation.”
In the citing paper
“acquired second-site Y96D mutations in KRASG12C confer clinical resistance to adagrasib by altering the switch 2 pocket such that the inhibitor can no longer bind69.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [69]
In the citing paper
“For example, RM-018 is a covalent KRASG12C inhibitor, but through its interaction with cyclophilin A, targets KRASG12C in the GTP-bound state; hence, RM-018 is a KRASG12C-on inhibitor69.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [69]
In the citing paper
“Pan-KRAS drugs would have advantages versus mutant-selective KRAS drugs in heterogeneous cancers driven by multiple KRAS alterations at baseline or upon development of acquired resistance due to secondary KRAS on-target alterations when compared to mutant-selective inhibitors (Fig. 3), with first examples emerging in the clinic (64–66).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [65]
In the citing paper
“This has been shown preclinically with the tricomplex KRASG12C active state inhibitor RM-018 in cellular models expressing a KRASG12C Y96D double mutant variant (65).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [65]
In the citing paper
“Preclinical and clinical data suggest that resistance to KRAS p.G12C inhibition is dependent on receptor tyrosine kinase activity, especially epidermal growth factor receptor (EGFR)-signalling.29 31 32”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [32]
In the citing paper
“correlative studies conducted in other KRASG12C-mutant tumor types treated with these inhibitors have demonstrated the emergence of pleiotropic resistance through both cell autonomous and non-cell autonomous mechanisms76–78.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [77]
In the citing paper
“Thereby, KRAS (Y96D) conferred resistance to KRAS (G12C) inhibitors in patient-derived KRAS (G12C) xenografts [96].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“RM-018, a neoteric KRAS (G12C) active state inhibitor, retains the ability to inhibit KRAS (G12C/Y96D) and may address the problem of drug resistance [96].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“Recently, a novel KRAS (Y96D) mutation was found, which affects the switch-II pocket and reduces the H-bonding between the Y96 residue of KRAS and MRTX849.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“It binds cyclophilin A, and this binary complex can associate with the active state of KRAS G12C and form a covalent bond.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [113]
In the citing paper
“Interestingly, KRAS Y96D confers resistance to currently approved (non-gluelike) covalent KRAS G12C inhibitors, and RM-018 overcomes such KRAS G12C/Y96D -mediated resistance.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Self-citationAnchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M. R., Zhelyazkova, B. H., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 913
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Cited by
Sorted by citations
Items 201–300 of 529
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Akhave, N. S., Biter, A. B., & Hong, D. S. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0356 · Cited by 17
Attili, I., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., Passaro, A., & de Marinis, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102957 · Cited by 19
Ma, J., Fu, S., Tan, J., Han, Y., Chen, Y., Deng, X., Shen, H., Zeng, S., Peng, Y., & Cai, C. (2025) · Advanced Science · doi:10.1002/advs.202502714 · Cited by 17
Conquering oncogenic KRAS and its bypass mechanisms
Hou, P., & Wang, Y. (2022) · Theranostics · doi:10.7150/thno.71260 · Cited by 18
Targeting KRAS G12C mutation in lung adenocarcinoma
Rohatgi, A., & Govindan, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.021 · Cited by 17
Manabe, T., & Bivona, T. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156891 · Cited by 17
KRAS inhibition in metastatic colorectal cancer: An update
Nusrat, M., & Yaeger, R. D. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102343 · Cited by 17
Lu, X., Jin, J., Wu, Y., Liu, X., Liang, X., Lin, J., Sun, Q., Qin, J., Zhang, W., & Luan, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21993 · Cited by 17
Self-citationErnst, S. M., Aldea, M. D., von der Thüsen, J. H., de Langen, A. J., Smit, E. F., Paats, M. S., Aerts, J. G. J. V., Mezquita, L., Popat, S., Besse, B., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01011-3 · Cited by 16
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Vetma, V., Puoti, I., Karolak, N. K., Chakraborti, S., Diers, E., Girardi, E., Khan, S., Kidd, G., Kropatsch, K., McLennan, R., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c10354 · Cited by 17
Kazi, A., Ranjan, A., Vasantha Kumar, M. V., Agianian, B., Chavez, M. G., Vudatha, V., Wang, R., Vangipurapu, R., Chen, L., Kennedy, P., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0222 · Cited by 16
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Rosell, R., Lewintre, E. J., Cao, P., Cai, X., Xing, B., Ito, M., Gomez-Vazquez, J. L., Marco-Jordán, M., Fariñas, S. C., Cardona, A. F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01667-x · Cited by 16
Baltanás, F. C., Kramer‐Drauberg, M., García‐Navas, R., Patrucco, E., Petrini, E., Arnhof, H., Juan, A. O.-S., Rodríguez-Ramos, P., Borrajo-Sánchez, J., Calzada, N., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422943122 · Cited by 16
CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer
Shirani-Bidabadi, S., Tabatabaee, A., Tavazohi, N., Hariri, A., Aref, A. R., Zarrabi, A., Casarcia, N., Bishayee, A., & Mirian, M. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151299 · Cited by 16
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia
Chen, Y., Yin, Z., Westover, K. D., Zhou, Z., & Shu, L. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0504 · Cited by 15
Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
Nagayama, S., Low, S., Kiyotani, K., & Nakamura, Y. (2021) · Cancers · doi:10.3390/cancers13194803 · Cited by 16
Li, Y., Han, L., & Zhang, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.02.018 · Cited by 16
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Brazel, D., Arter, Z., & Nagasaka, M. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s383662 · Cited by 16
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
Bungaro, M., Novello, S., & Passiglia, F. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01033-4 · Cited by 15
Genetic mutations affecting mitochondrial function in cancer drug resistance
Lee, C., Park, S., & Yoon, S. K. (2023) · Genes & Genomics · doi:10.1007/s13258-022-01359-1 · Cited by 15
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Moldvay, J., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 15
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Scardaci, R., Berlinska, E., Scaparone, P., Michelina, S. V., Garbo, E., Novello, S., Santamarı́a, D., & Ambrogio, C. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13605 · Cited by 14
SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
Lilja, J., Kaivola, J., Conway, J. R. W., Vuorio, J., Parkkola, H., Roivas, P., Dibus, M., Chastney, M. R., Varila, T., Jacquemet, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52326-1 · Cited by 14
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 17
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways
Yin, C., Alqahtani, A. J., & Noel, M. S. (2022) · Cancers · doi:10.3390/cancers14112619 · Cited by 14
Addressing Drug Resistance in Cancer: A Team Medicine Approach
Kulkarni, P., Mohanty, A. R., Bhattacharya, S., Singhal, S. S., Guo, L., Ramisetty, S. K., Mirzapoiazova, T., Mambetsariev, B., Mittan, S., Malhotra, J. D., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195701 · Cited by 14
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
Sealover, N. E., Theard, P. L., Hughes, J. M., Linke, A. J., Daley, B. R., & Kortum, R. L. (2023) · iScience · doi:10.1016/j.isci.2023.108711 · Cited by 14
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 15
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13
Self-citationÁlvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., Arenas, A. M., Hernández-Navas, I., Benitez‐Cantos, M. S., Andrades, Á., Fariñas, S. C., Lewintre, E. J., Paz-Ares, L. G., Ferrer, I., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62350-4 · Cited by 15
Wang, K., Zhang, X., Fan, Y., Zhou, L. F., Duan, Y., Su, L., Sun, Z., Zhang, C., Yang, H., Yuan, W., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103419 · Cited by 13
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
The complex journey of targeting RAS in oncology
Wasiak, K., Ciunowicz, D., Kierasińska, A., Węgierska, M., Pacholczyk, M., Rieske, P., & Stoczyńska-Fidelus, E. (2025) · BMC Cancer · doi:10.1186/s12885-025-14033-y · Cited by 14
Han, Z., Zhou, D., Wang, J., Jiang, B., & Liu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188677 · Cited by 13
Rafael, D. F. D. S., Montero, S., Carcavilla, P., Andrade, F., German-Cortés, J., Díaz‐Riascos, Z. V., Seras‐Franzoso, J., Munive, M. L., Fernández, B., Pereira, A., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19897 · Cited by 13
Finally, Effective Inhibitors of Mutant KRAS
Rosen, N. X. (2021) · New England Journal of Medicine · doi:10.1056/nejme2107884 · Cited by 14
Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinomaPreprint
Fort, G., Arnold, H., Camolotto, S. A., O’Toole, K. T., Tariq, R., Waters, A. K., Gillis, K., & Snyder, E. L. (2025) · Genes & Development · doi:10.1101/gad.352742.125 · Cited by 13
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“Acquired AZ’1569-R clones display KRAS amplification and activation of several RTKs Prior studies indicated that tumors with acquired resistance to KRAS agents can have multiple resistance mechanisms, including alterations within the RAS/MAPK pathway and bypass activating alterations (28, 29).”
BackgroundKeane, F., Chou, J. F., Walch, H. S., Schoenfeld, J. D., Singhal, A., Cowzer, D., Harrold, E. C., O'Connor, C. A., Park, W., Varghese, A. M., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae095 · Cited by 12
Parry, C., Pellicano, F., Schüttelkopf, A. W., Beyer, K. S., Bower, J. F., Bryson, A., Cameron, K., Cerutti, N. M., Clark, J. P., Davidson, S. C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02929 · Cited by 12
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC
Tran, N. L., Jiang, J., Ma, M., Gadbois, G. E., Gulay, K. C. M., Verano, A. L., Schiavon, C. R., Rebollo, E., Zhou, H., Huang, C., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01978-1 · Cited by 14
Cheng, M. L., Lee, J., Kumar, R., Klein, H., Raskina, K., Schrock, A. B., Michael, K., Mazor, T., Cerami, E. G., Oxnard, G. R., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00382 · Cited by 12
Toward Precision Medicine in Atopic Dermatitis Using Molecular-Based Approaches
Carrascosa, J. M., Aterido, A., Li, T., Guillén, Y., Martinez, S., Marsal, S., & Julià, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.08.003 · Cited by 13
KRAS-Targeted Therapies in Advanced Solid Cancers: Drug the Undruggable?
Saleh, K., Kordahi, M., Felefly, T., Kourié, H. R., & Khalife, N. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0045 · Cited by 12
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer
Hwang, G., Yuen, J. G., Fesler, A. T., Farley, H., Haley, J. D., & Ju, J. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.007 · Cited by 11
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Fey, S. K., Najumudeen, A. K., Watt, D. M., Millett, L. M., Ford, C. A., Gilroy, K. L., Simpson, R. J., McLay, K., Upstill‐Goddard, R., Chang, D. K.-F., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2709 · Cited by 11
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Wu, J., Xie, K., Zhang, Y., Zhang, W., Cheng, R., Zhang, Y., Xia, Y., Liu, T., Yin, R. H., Qiu, Y., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03369-9 · Cited by 11
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 11
Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers
Chareddy, Y. S., Huggins, H. P., Sahoo, S. S., Stanland, L. J., Gutierrez-Ford, C., Whately, K. M., Edatt, L., Azam, S. H., Fleming, M. C., Im, J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187204 · Cited by 11
Niitsu, Y., Sato, Y., & Takayama, T. (2022) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.98.005 · Cited by 11
Xiao, F., Wang, K., Wang, X., Li, H., Hu, Z., Ren, X., Huang, W., Feng, T., Yao, L., Lin, J., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0049 · Cited by 10
Self-citationFGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer
Kazi, A., Vasiyani, H., Ghosh, D., Bandyopadhyay, D., Shah, R. D., Vudatha, V., Trevino, J., & Sebti, S. M. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.11.022 · Cited by 10
Nondegradative Synthetic Molecular Glues Enter the Clinic
Repity, M. L., Deutscher, R. C. E., & Hausch, F. (2025) · ChemMedChem · doi:10.1002/cmdc.202500048 · Cited by 10
Solanki, H. S., Shah, H., Imbody, D. J., Desai, B., Kato, R., Miroshnychenko, D., Stern, Y. E., Majumder, A., Sarcar, B., Xieraili, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0600 · Cited by 10
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 12
Stahlhut, C. E., Maciag, A. E., Sullivan, K. A., Singh, K., Gitego, N., Zhang, Z., Chan, A. H., Sharma, A. K., Alexander, P., Shu, J., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1280 · Cited by 10
RAS-mediated tumor stress adaptation and the targeting opportunities it presents
Redding, A., Aplin, A. E., & Grabocka, E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049280 · Cited by 11
Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
Arbour, K. C., & Lito, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00562 · Cited by 10
Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
Lee, C., Yi, J., Park, J., Ahn, B., Won, Y.-W., Jeon, J., Lee, B. J., Cho, W. J., & Park, J. W. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06436-9 · Cited by 9
Vascular malformations: from genetics to therapeutics
Morin, G., Galasso, I., & Canaud, G. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00344-x · Cited by 9
Bhattacharya, D., Roman, B., & Reddy, S. (2026) · Cancer Gene Therapy · doi:10.1038/s41417-026-01003-0 · Cited by 9
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Andrade, F., German-Cortés, J., Montero, S., Carcavilla, P., Baranda-Martínez-Abascal, D., Moltó‐Abad, M., Seras‐Franzoso, J., Díaz‐Riascos, Z. V., Rafael, D. F. D. S., & Abasolo, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061686 · Cited by 9
Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II
Gebregiworgis, T., Chan, J. Y.-L., Kuntz, D. A., Privé, G. G., Marshall, C. B., & Ikura, M. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151414 · Cited by 10
López-Estévez, A. M., Sanjurjo, L., Turrero, Á., Arriaga, I., Abrescia, N. G. A., Poveda, A. M., Jiménez‐Barbero, J., Vidal, A., Torres, D., & Alonso, M. J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.032 · Cited by 9
Peng, T., Wu, T., Yi, T.-Y., & Wu, A. (2024) · Cancers · doi:10.3390/cancers16213676 · Cited by 9
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)
Xu, Q., Zhang, G., Liu, Q., Li, S., & Zhang, Y. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2032648 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 10
Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations
Yenerall, P. M., Kollipara, R. K., Avila, K., Peyton, M., Eide, C. A., Bottomly, D., McWeeney, S. K., Liu, Y., Westover, K. D., Druker, B. J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1153 · Cited by 10
Hu, Q., Feng, J., Qi, L., & Jin, Y. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10404 · Cited by 9
Phospholipid Metabolism Reprogramming of Cancer Stem Cells and Its Impacts on Stemness
Wang, Q., Cai, L., Tang, S., Pan, D., Wang, Z., Chen, Q., Zhou, Y., & Shen, Y. (2025) · Biocell · doi:10.32604/biocell.2025.060045 · Cited by 8
Leini, R., Kapp, J. N., Kopra, K., & Pantsar, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-07532-2 · Cited by 8
Optimizing KRAS Therapeutics for Non–Small Cell Lung Cancer
Lim, J. U., Negrao, M. V., & Hong, D. S. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-115849 · Cited by 9
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Lim, S.-A., Todd, H., Goodhart, G., Chang, W.-H., Amparo, A. M., Bridgens, R., Dilly, J., Park, S. J., Beal, R. M., Shehadeh, S. M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1835 · Cited by 10
Alanazi, F. E., Alatawi, Y. M., Alattar, A., Alshaman, R., Kotb, A. A., & Hetta, . F. (2025) · Pharmaceuticals · doi:10.3390/ph18121788 · Cited by 8
KRAS Inhibition in Pancreatic Ductal Adenocarcinoma
Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020873 · Cited by 8
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Condakes, M. L., Zhang, Z., Danahy, D. B., Moore, R. R., Lakkaraju, S. K., Zhuo, X., Amako, Y., Borzilleri, R. M., Balachander, S. B., Chourb, L. S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69003-0 · Cited by 8
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer
Alonso, S., Chu, K., Granowsky, E., Saraiba-Rabanales, V., Parsons, M. J., Gunasinghe, H. I., Shia, J., Yaeger, R., & Dow, L. E. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.009 · Cited by 8
TargetingKRAS G12Cmutations in colorectal cancer
Zhao, M., & Wu, A. (2022) · Gastroenterology report · doi:10.1093/gastro/goac083 · Cited by 9
Insights into how adeno-squamous transition drives KRAS inhibitor resistance
Hu, F., & Lito, P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.014 · Cited by 8
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Novoplansky, O., Jagadeeshan, S., Prasad, M., Yegodayev, K. M., Marripati, D., Shareb, R. A., Greenshpan, Y., Mathukkada, S., Lulu, T. B., Bhattacharya, B., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03227-0 · Cited by 8
Li, L., Feng, R., Li, Y., Yu, X., Liu, Y., Zhao, Y., & Liu, Z. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.013 · Cited by 8
Pinnelli, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0609 · Cited by 8
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“The genetic alterations identified in these studies are highly heterogeneous and may mediate therapeutic resistance via diverse mechanisms, such as changing inhibitor binding affinity, re-activating KRAS activity, and bypassing KRAS ‐ mediated signaling [56, 58].”
Live-cell target engagement of allosteric MEKi on MEK–RAF/KSR–14-3-3 complexes
Marsiglia, W. M., Chow, A., Khan, Z. M., Liu, H., & Dar, A. C. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01454-8 · Cited by 7
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 7
Shin, D. H., Choi, M., Han, C., & Kim, S. S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01536-8 · Cited by 7
Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Wang, L., Wei, D., Li, S., & Jiang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03569-x · Cited by 7
Identification and characterization of binders to a cryptic and functional pocket in KRAS
Beyer, K. S., Klein, J., Katz, S., Welker, P., Lanter, M., Guthy, D. A., Pollehn, K., Gluck-Gadé, A., Bleu, M., Desogus, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65844-3 · Cited by 7
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors
Mouti, M. A., & Pauklin, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.004 · Cited by 7
Li, N., Liu, C., Zhang, W., & Rao, G. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258913231019113814 · Cited by 7
Ghai, S., Shrestha, R., & Su, K. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1500880 · Cited by 7
Yang, E.-W., Waldrup, B., & Velazquez-Villarreal, E. I. (2025) · Biomedicines · doi:10.3390/biomedicines13081835 · Cited by 7
Burska, A. N., Ilyassova, B., Dildabek, A., Khamijan, M., Бегимбетова, Д., Molnár, F., & Sarbassov, D. D. (2022) · Cells · doi:10.3390/cells11213454 · Cited by 7
Begovich, K., Schoolmeesters, A., Rajapakse, N., Martínez‐Terroba, E., Kumar, M., Shakya, A., Lai, C., Greene, S., Whitefield, B., Okano, A., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0513 · Cited by 7
Theardy, M. S., Takeda, M., Sorokin, A., Chen, S., Yang, Z., Wang, X., Kanikarla, P., Coker, O., Nguyen, P., Wei, Y., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102253 · Cited by 6
Ismail, M., Davies, G., Sproat, G., Monteverde, T., Tart, J., Acebrón-García-de-Eulate, M., Gohlke, A., Hancock, D., Adhikari, S., Stefanovic-Barrett, S., et al. (2024) · SLAS Discovery · doi:10.1016/j.slasd.2024.100197 · Cited by 6
Metadata
- Authors
- Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., Baiev, I., Juric, D., Gainor, J. F., Klempner, S. J., Lennerz, J. K., Siravegna, G., Bar-Peled, L., Hata, A. N., Heist, R. S., & Corcoran, R. B.
- Affiliations
- Harvard University (US)
- Guardant (United States) (US)
- Massachusetts General Hospital (US)
- 1Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.
- Corresponding author
- Hata, Aaron N.
- Heist, Rebecca S.
- Corcoran, Ryan B.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 8
- Pages
- 1913-1922
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8338755
- OpenAlex
- W3142010099
- Cited by
- 527
- References
- 29
- Citations by year
- 2026: 85 · 2025: 100 · 2024: 124 · 2023: 91 · 2022: 86 · 2021: 41
- FWCI
- 26.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Revolution Medicines (RM-018)
- Stand Up To Cancer—American Cancer Society Lung Cancer Dream Team Translational Research Grant (SU2C-AACR-DT17–15)
- NIH (R01-CA164273, 1F32CA250231–01)
- AACR (19–20–45-BARP)
- Damon Runyon (DRR-62–20)
- NIH NCI (R00 CA215249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, acquired drug resistance, switch-II pocket, adagrasib, sotorasib, non-small cell lung cancer, NRAS, BRAF, MEK1, drug-protein binding
- MeSH terms
- Acetonitriles, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Neoplasm Metastasis, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
